

Cadonilimab

Cat. No.:	HY-P99117
CAS No.:	2394841-59-7
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer ^{[1][2]} .
IC ₅₀ & Target	PD1 ^[1]

REFERENCES

- [1]. Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. *Pharmaceuticals* (Basel). 2021 Aug 31;14(9):884.
- [2]. Kaplon H, et al. Antibodies to watch in 2022. *MAbs*. 2022 Jan-Dec;14(1):2014296.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA